TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01046825
Drug: COP, COPD M3, CYM
Approvals — FDA: no, EMA: no, PMDA: no
Description: GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted.
Study: NCT03929640
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg tablet every 6 hours
Study: NCT03929640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet every 6 hours
Study: NCT03929640
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600 mg tablet every 6 hours
Study: NCT01681199
Drug: Fluvastatin extended release tablet
Normalized name: fluvastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01746277
Drug: combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
Study: NCT01746277
Drug: Sequenced group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
Study: NCT01327027
Drug: Placebo; Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
Study: NCT00305539
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00610311
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
Study: NCT02458677
Drug: PRX003
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02615340
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
Study: NCT02615340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
Study: NCT04218773
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As an alternative to intravenous phenylephrine, intravenous norepinephrine can be used with an initial infusion rate of 3 mcg/min. The initial infusion rate of norepinephrine will be adjusted at 1 mcg/min increments at 3-minute intervals to achieve and maintain the target blood pressure. Maximum dose is 25 mcg/min. Combination therapy with both agents (phenylephrine and norepinephrine) to achieve and maintain blood pressure targets is not permitted.
Study: NCT01860807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00746434
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream
Study: NCT02874573
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01274559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
Study: NCT00280085
Drug: Arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02575170
Drug: Ringer's lactate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of Ringer's lactate solution
Study: NCT02215330
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03600649
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m2/day on Days 1 thru 5 of a 21-day cycle
Study: NCT02106494
Drug: APF530
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02106494
Drug: APF530 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02129816
Drug: Bryophyllum
Normalized name: Bryophyllum (Argento Cultum)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00753883
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 20 mg/QD for 6 Weeks.
Study: NCT00720902
Drug: growth hormone releasing hormone (GHRH) & arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
Study: NCT02650986
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02208037
Drug: Methotrexate (ARM with Maraviroc)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of maraviroc. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
Study: NCT02208037
Drug: Methotrexate (ARM with Bortezomib)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of bortezomib. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
Study: NCT01556698
Drug: NVN1000
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01556698
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01551316
Drug: MN-221
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
Study: NCT01551316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
Study: NCT02208037
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hydration prior to cyclophosphamide may be given according to institutional standards.~Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if ABW \< IBW, use ABW\] will be given on Day 3 post-transplant (between 60 and 72 hours after the start of the HSCT) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
Study: NCT01836198
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01836198
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01334944
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
Study: NCT02305381
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
Study: NCT04380298
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30ml of local infiltration solution containing 60mg ropivacaine
Study: NCT04380298
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30ml of local infiltration solution containing 0.1mg epinephrine
Study: NCT00369681
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02192723
Drug: Typical antipsychotic
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks
Study: NCT02627898
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, 400mg 1 time daily with the first bite of eat meal
Study: NCT01847976
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
Study: NCT02163655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days
Study: NCT02308098
Drug: Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02308098
Drug: Symbicort Turbuhaler 320/9 ug/inhalation 1inh
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02308098
Drug: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02308098
Drug: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01582503
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous repeating dose
Study: NCT04603833
Drug: SHR3680
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SHR3680
Study: NCT03516045
Drug: 18F-AlF-NOTA-neurotensin
Normalized name: NEUROTENSIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of the radioligand 18F-AlF-NOTA-neurotensin
Study: NCT02205541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~ECZ or placebo will be administrated intravenously as a 30-minute injection
Study: NCT00041756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet, twice daily for for one year
Study: NCT04472988
Drug: Treatment as Usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
Study: NCT01073800
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03082716
Drug: Custodiol Solution
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: After cross clamping patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
Study: NCT03082716
Drug: Blood cardioplegia
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: After cross clamping patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
Study: NCT01329939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-dependent dose, nightly, 24 weeks
Study: NCT00185224
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo
Study: NCT05859802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking a placebo pill two times day
Study: NCT01118455
Drug: Anti-Epileptic Drug (AED)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
Study: NCT00757978
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of placebo twice a day
Study: NCT02969629
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04369950
Drug: 2% lidocaine with 1:200,000 epinephrine and epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
Study: NCT03430063
Drug: SDREGN2810
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose intravenous (IV) infusion
Study: NCT03430063
Drug: SDREGN2810/ipi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy dose IV
Study: NCT03430063
Drug: HDREGN2810
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose IV
Study: NCT00544791
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg, oral, daily dose for 6 months
Study: NCT00544791
Drug: placebo like melatonin tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01995019
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml intra-articular placebo
Study: NCT01584492
Drug: CHF 1535 50/6 (2 inhalations)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
Study: NCT01584492
Drug: CHF 1535 50/6 (4 inhalations)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
Study: NCT01584492
Drug: Placebo (6 inhalations)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo via pMDI
Study: NCT05099913
Drug: Deanxit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central neuromodulators was applied in refractory FD patients for different time
Study: NCT04538989
Drug: RZ358 Sequential Group Cohort 1
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)
Study: NCT04538989
Drug: RZ358 Sequential Group Cohort 2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)
Study: NCT04538989
Drug: RZ358 Sequential Group Cohort 3
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)
Study: NCT04538989
Drug: RZ358 Sequential Group Cohort 4
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)
Study: NCT00790920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, single bolus over 1 - 2 minutes on 1st day
Study: NCT00087659
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03075904
Drug: ALXN1830
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via IV infusion.
Study: NCT04360876
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo delivered intravenously on the same dosing schedule as dexamethasone
Study: NCT01691040
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT03120299
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
Study: NCT01797978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04620031
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h
Study: NCT01099683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive rectal suppository containing placebo
Study: NCT00317876
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00317876
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02854358
Drug: mixed powder of A. digitata and M. sylvestris
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02854358
Drug: Hypozalix spray (artificial saliva)
Normalized name: Dunaliella salina extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypozalix spray (artificial saliva)
Study: NCT00815347
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
Study: NCT00010842
Drug: Essential fatty acids
Normalized name: essential fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00817336
Drug: D Serine
Normalized name: Wall-associated serine proteinase
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg/day
Study: NCT00817336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00866918
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00866918
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00866918
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02486159
Drug: Herbal plaster (Sanfujiu)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.
Study: NCT01100060
Drug: azithromycin (AZ) microsphere
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZ microsphere (2000 mg) single dose on Day 1.
Study: NCT01100060
Drug: azithromycin (AZ)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZ IR 4 x 500 mg tablets, single dose on Day 1.
Study: NCT03551808
Drug: using of Ketorolac Tromethamine Eye Drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: using of Ketorolac Tromethamine Eye Drop one day before the surgery in each 8 hours and continue it for 4 weeks after the surgery
Study: NCT03318783
Drug: GSK2256294
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
Study: NCT03318783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered in a single dose once daily enteral for a duration of 10 days.